Latest Insider Transactions at 89bio, Inc. (ETNB)
This section provides a real-time view of insider transactions for 89bio, Inc. (ETNB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of 89bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of 89bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2023
|
Ryan Martins Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,592
-4.4%
|
$43,104
$12.91 P/Share
|
|
Feb 03
2023
|
Ryan Martins Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+7.15%
|
$9,000
$3.11 P/Share
|
|
Feb 01
2023
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
680
-0.99%
|
$8,160
$12.05 P/Share
|
|
Feb 01
2023
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
408
-1.12%
|
$4,896
$12.05 P/Share
|
|
Feb 01
2023
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
695
-1.06%
|
$8,340
$12.05 P/Share
|
|
Jan 03
2023
|
Ryan Martins Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,947
-14.05%
|
$71,364
$12.51 P/Share
|
|
Nov 15
2022
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,113
-4.33%
|
$28,017
$9.79 P/Share
|
|
Nov 15
2022
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+11.12%
|
-
|
|
Oct 18
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,172,741
+11.58%
|
$8,209,187
$7.65 P/Share
|
|
Sep 30
2022
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,297
-1.94%
|
$6,485
$5.79 P/Share
|
|
Sep 30
2022
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+5.32%
|
-
|
|
Sep 28
2022
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
2,882
-4.38%
|
$14,410
$5.76 P/Share
|
|
Sep 28
2022
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
8,333
+11.24%
|
-
|
|
Sep 28
2022
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,018
-4.55%
|
$10,090
$5.76 P/Share
|
|
Sep 28
2022
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,833
+11.63%
|
-
|
|
Sep 28
2022
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,882
-4.38%
|
$14,410
$5.76 P/Share
|
|
Sep 28
2022
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,333
+11.24%
|
-
|
|
Sep 28
2022
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,527
-4.99%
|
$57,635
$5.76 P/Share
|
|
Sep 28
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,333
+12.61%
|
-
|
|
Sep 09
2022
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+30.3%
|
-
|
|
Sep 09
2022
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+28.04%
|
-
|
|
Sep 09
2022
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+30.3%
|
-
|
|
Sep 08
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+33.6%
|
$100,000
$1.93 P/Share
|
|
Jul 01
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
2,816,900
+26.58%
|
$8,450,700
$3.55 P/Share
|
|
Apr 25
2022
|
Michael R Hayden |
BUY
Open market or private purchase
|
Indirect |
10,000
+8.77%
|
$20,000
$2.67 P/Share
|
|
Apr 07
2022
|
Michael R Hayden |
BUY
Open market or private purchase
|
Indirect |
10,000
+9.62%
|
$30,000
$3.48 P/Share
|
|
Mar 30
2022
|
Michael R Hayden |
BUY
Open market or private purchase
|
Indirect |
6,250
+6.93%
|
$18,750
$3.62 P/Share
|
|
Feb 17
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,200
+35.14%
|
-
|
|
Feb 17
2022
|
Harry H Mansbach Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+26.11%
|
-
|
|
Feb 17
2022
|
Quoc Le Nguyen |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+26.11%
|
-
|
|
Feb 17
2022
|
Ryan Martins Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+25.06%
|
-
|
|
Feb 17
2022
|
Ram Waisbourd Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,750
+36.11%
|
-
|
|
Feb 05
2022
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,363
-4.19%
|
$6,815
$5.23 P/Share
|
|
Feb 05
2022
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,088
-4.09%
|
$20,440
$5.23 P/Share
|
|
Feb 05
2022
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,022
-4.35%
|
$5,110
$5.23 P/Share
|
|
Feb 05
2022
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,363
-4.19%
|
$6,815
$5.23 P/Share
|
|
Feb 01
2022
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$35,000
$5.7 P/Share
|
|
Feb 01
2022
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+40.0%
|
$7,000
$1.93 P/Share
|
|
Jan 28
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+5.17%
|
$15,000
$6.14 P/Share
|
|
Jan 27
2022
|
Rohan Palekar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+10.34%
|
$35,000
$7.5 P/Share
|
|
Jan 26
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
21,482
-0.58%
|
$171,856
$8.38 P/Share
|
|
Jan 25
2022
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,091
-1.32%
|
$392,728
$8.4 P/Share
|
|
Dec 16
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$77,000
$11.48 P/Share
|
|
Dec 16
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Nov 16
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$112,000
$16.49 P/Share
|
|
Nov 16
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Oct 18
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$119,000
$17.49 P/Share
|
|
Oct 18
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|
|
Sep 16
2021
|
Ram Waisbourd Officer |
SELL
Open market or private sale
|
Direct |
7,000
-100.0%
|
$133,000
$19.46 P/Share
|
|
Sep 16
2021
|
Ram Waisbourd Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+50.0%
|
$7,000
$1.93 P/Share
|